v3.26.1
Segment Reporting and Disaggregation of Relevant Expense Captions (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents information about reported segment revenues, segment profit, and significant segment expenses.
Three Months Ended
March 31,
(in millions)20262025
Revenues:
INGREZZA net product sales$656.9 $545.2 
CRENESSITY net product sales153.3 14.5 
Other revenues (1)
4.3 12.9 
Total revenues814.5 572.6 
Less:
Cost of revenues13.8 9.2 
Research and development:
External research and development 148.0 107.9 
Payroll and benefits84.5 75.0 
Milestones22.6 45.4 
Other research and development (2)
41.1 34.9 
Total research and development296.2 263.2 
Acquired in-process research and development21.2 0.1 
Selling, general, and administrative318.5 276.5 
Gain on sale of business, net of transaction costs
(28.6)— 
Unrealized (gain) loss on equity investments
(25.3)30.6 
Investment income and other, net
(28.1)(21.7)
Provision for income taxes
48.9 6.8 
Net income
$197.9 $7.9 
_________________________
(1) Other revenues primarily consist of royalties earned on AbbVie net sales of elagolix and Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation) net sales of valbenazine.
(2) Other research and development consists of indirect costs incurred for the benefit of multiple research and development programs, including facility-based expenses (such as rent expense) and other overhead allocations.